International Journal of Drug Delivery Technology
Volume 15, Issue 1

Formulation and Characterization of Ozenoxacin 1% Cream for Treatment of Impetigo 

Deepika*, Rajendra Pal Singh Rathore 

Department of Pharmacy, Bhupal Nobles' University, Udaipur, Rajasthan 

Received: 28th Nov, 2024; Revised: 30th Dec, 2024; Accepted: 17th Feb, 2025; Available Online: 25th Mar, 2025

ABSTRACT

A new cream has been developed those features 1% active oxenoxacin, a topical antibacterial that effectively kills gram-positive bacteria. It's specifically designed to tackle impetigo, which is a bacterial skin ailment that spreads easily. A cream with 1% ozenoxacin is in the works to tackle bacterial skin infections, especially impetigo, which affects both adults and kids (from two months old). This product is specifically designed for treating impetigo. The cream's inactive components are well-known and frequently seen in topical medications, chosen based on a study that looked at how they interact with the drug. Ozenoxacin is a novel, fast-acting topical antibiotic, has a good microbiological profile, and is considered safe. However, it’s really important to use it responsibly and follow antimicrobial stewardship practices to keep this innovative treatment effective.

KEYWORDS: Topical cream, Antibiotics, Ozenoxacin, Impetigo.

How to cite this article: Deepika, Rajendra Pal Singh Rathore. Formulation and Characterization of Ozenoxacin 1% Cream for Treatment of Impetigo. International Journal of Drug Delivery Technology. 2025;15(1):266-70. doi: 10.25258/ijddt.15.1.37

REFERENCES

  1. Food and Drug Administration. XepiTM (ozenoxacin) cream, for topical use [Internet]. 2017 [cited 2019 February 20].
  2. Canton R, Morrissey I, Vila J, Tato M, García-Castillo M, López Y, Gargallo-Viola D, Zsolt I. Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates. Future Microbiology. 2018;13(sup6):3-19. doi: 10.2217/fmb-2017-0289.
  3. López Y, Tato M, Espinal P, Garcia-Alonso F, Gargallo-Viola D, Cantón R, Vila J. In vitro activity of ozenoxacin against quinolone-susceptible and quinolone-resistant Gram-positive bacteria. Antimicrobial Agents and Chemotherapy. 2013;57(12):6389-6392. doi: 10.1128/AAC.01509-13.
  4. González Borroto JI, Awori MS, Chouinard L, Smith SY, Tarrago C, Blazquez T, Gargallo-Viola D, Zsolt I. Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs. Future Microbiology. 2018;13(sup6):31-40. doi: 10.2217/fmb-2018-0095.
  5. Vila J, Hebert AA, Torrelo A, López Y, Tato M, García-Castillo M, Cantón R. Ozenoxacin: a review of preclinical and clinical efficacy. Expert Review of Anti-infective Therapy. 2019;17(3):159-168. doi: 10.1080/14787210.2019.1573671.
  6. Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: an update. International Journal of Dermatology. 2003;42(4):251–255. doi: 10.1046/j.1365-4362.2003.01755.x.
  7. Cole C, Gazewood J. Diagnosis and treatment of impetigo. American Family Physician. 2007;75(6):859-864.
  8. Sladden MJ, Johnston GA. Common skin infections in children. BMJ. 2004;329(7457):95-99. doi: 10.1136/bmj.329.7457.95.
  9. Sladden MJ, Johnston GA. Current options for the treatment of impetigo in children. Expert Opinion on Pharmacotherapy. 2005;6(13):2245-2256. doi: 10.1517/14656566.6.13.2245.
  10. Hebert AA, Rosen T, López NA, Zsolt I, Masramon X. Safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo. International Journal of Women's Dermatology. 2020;6(2):109-115. doi: 10.1016/j.ijwd.2020.01.004.
  11. American Academy of Pediatrics, Committee on Infectious Diseases; Kimberlin DW, Brady MT, Jackson MA, Long SS (eds). Red Book. 2015 Report of the Committee on Infectious Diseases, 30th edition [Internet]. 2015 [cited 2019 April 9].
  12. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2014;59(2):e10-e52. doi: 10.1093/cid/ciu444.
  13. Gropper S, Cepero AL, Santos B, Kruger D. Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo. Future Microbiology. 2014;9(sup8):S33-S40. doi: 10.2217/fmb.14.85.
  14. Gropper S, Albareda N, Chelius K, Kruger D, Mitha I, Vahed Y, Gani M, García-Alonso F, Ozenoxacin in Impetigo Trial Investigators Group. Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. Future Microbiology. 2014;9(9):1013-1023. doi: 10.2217/fmb.14.78.
  15. Torrelo A, Grimalt R, Masramon X, Albareda López N, Zsolt I. Ozenoxacin, a new effective and safe topical treatment for impetigo in children and adolescents. Dermatology. 2020;236(3):199-207. doi: 10.1159/000504536.
  16. Paller AS, Hawk JL, Honig P, Giam YC, Hoath S, Mack MC, Stamatas GN. New insights about infant and toddler skin: implications for sun protection. Pediatrics. 2011;128(1):92-102. doi: 10.1542/peds.2010-3679.
  17. Nareswari TL, Vrince FO, Syafitri E. Formulation and evaluation of citronella oil (Cymbopogon nardus (L.) Rendle) cream for acne treatment. International Journal of Drug Delivery Technology. 2023;13(1):418-422.
  18. Deepika, Rathore RPS. A Comprehensive Review on Ozenoxacin Cream for Treatment of Impetigo. International Journal of Drug Delivery Technology. 2024;14(4):2433-38 doi: 10.25258/ijddt.14.4.65